Program
carfilzomib
Also written as “Carfilzomib”, “Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®)” and “Drug: Carfilzomib + Dexamethasone”.
Its studies are mostly in Multiple Myeloma · Amyloidosis · Small Cell Lung Carcinoma · Ovarian Neoplasms · Waldenstrom Macroglobulinemia, led by 5 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amgen | 230 open or running | phase 4since Apr 16, 2019 | Sep 6, 2005 | none ahead |
| AbbVie | 32 open or running | phase 3since Nov 28, 2023 | Sep 27, 2013 | Jun 2027phase 2 · NCT02899052 |
| Criterium | 30 open or running | phase 2since Oct 19, 2011 | Oct 19, 2011 | none ahead |
| Oncotherapeutics | 20 open or running | phase 2since Jan 3, 2013 | Jan 3, 2013 | none ahead |
| Sanofi | 22 open or running | phase 2since Jan 20, 2023 | Jan 20, 2023 | Apr 1, 2027phase 2 · NCT06356571 |
Also a collaborator on its studies: Bristol-Myers Squibb and onyx-therapeutics-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 20 studies since Sep 6, 2005.
- Nov 6, 2013Phase 2 study in Small Cell Lung CarcinomaAmgen · NCT01987232 · 32 enrolled · United States, Canada, Russian Federation
- Dec 23, 2014Phase 1 study in Multiple MyelomaAmgen · NCT02335983 · 107 enrolled · United States
- Apr 6, 2015Phase 3 study in Multiple MyelomaAmgen · NCT02412878 · 478 enrolled · United States, Australia, Belgium and more
- Sep 1, 2016Phase 2 study in Multiple MyelomaAbbVie · NCT02899052 · 120 enrolled · United States, Australia, Hungary and more
- Nov 11, 2016Phase 3 study in RecurrenceAmgen · NCT03029234 · 126 enrolled · China
- Feb 27, 2017Phase 2 study in Multiple MyelomaOncotherapeutics · NCT03104270 · 13 enrolled · United States
- Apr 2, 2018Phase 2 study in RecurrenceAmgen · NCT03512353 · 7 enrolled · United States
- Jan 14, 2019Phase 3 study in RecurrenceAmgen · NCT03859427 · 454 enrolled · United States, Austria, Bulgaria and more
- Apr 16, 2019Phase 4 study in Multiple MyelomaAmgen · NCT03934684 · 101 enrolled · India
- Nov 22, 2019Phase 2 study in RecurrenceAmgen · NCT04191616 · 54 enrolled · United States, Denmark, Estonia and more
- Jan 20, 2023Sanofi's first study: phase 2 study in Multiple MyelomaNew to SanofiSanofi · NCT05704049 · 118 enrolled · Australia, Brazil, China and more
- Nov 28, 2023Phase 3 study in Multiple MyelomaAbbVie · NCT06158841 · 421 enrolled · United States, Australia, Austria and more
- Apr 5, 2024Phase 2 study in Plasma Cell Myeloma RefractorySanofi · NCT06356571 · 64 enrolled · United States
- Oct 26, 2026Primary completion moved from 2027-01-08 to 2027-04-01Date moved laterphase 2 · +3 months · NCT06356571
Ahead
- Apr 1, 2027Primary completion: phase 2 study in Plasma Cell Myeloma RefractorySanofi · NCT06356571
- Jun 2027Primary completion: phase 2 study in Multiple MyelomaAbbVie · NCT02899052
- Dec 2027Primary completion: phase 3 study in Multiple MyelomaAbbVie · NCT06158841
TargetBeta
“26S proteasome inhibitor”ChEMBL 37, by rule
Other programs on the same 38 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Bortezomibrule | Johnson & Johnson | phase 4 | 85 |
Studies
All 33 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06356571Plasma Cell Myeloma Refractory · United States | 2 | Active, not recruiting | Sanofi | Apr 1, 2027 | 64 |
| NCT06158841Multiple Myeloma · United States, Australia, Austria and more | 3 | Active, not recruiting | AbbVie | Dec 2027 | 421 |
| NCT05704049Multiple Myeloma · Australia, Brazil, China and more | 2 | Active, not recruiting | Sanofi | Dec 22, 2025 | 118 |
| NCT04191616Recurrence · United States, Denmark, Estonia and more | 2 | Completed | Amgen | Nov 30, 2022 | 54 |
| NCT03934684Multiple Myeloma · India | 4 | Completed | Amgen | Mar 23, 2023 | 101 |
| NCT03859427Recurrence · United States, Austria, Bulgaria and more | 3 | Completed | Amgen | Mar 31, 2023 | 454 |
| NCT03512353Recurrence · United States | 2 | Terminated | Amgen | Jan 16, 2020 | 7 |
| NCT03104270Multiple Myeloma · United States | 2 | Terminated | Oncotherapeutics | Oct 25, 2019 | 13 |
| NCT03029234Recurrence · China | 3 | Completed | Amgen | Nov 5, 2018 | 126 |
| NCT02899052Multiple Myeloma · United States, Australia, Hungary and more | 2 | Active, not recruiting | AbbVie | Jun 2027 | 120 |
| NCT02412878Multiple Myeloma · United States, Australia, Belgium and more | 3 | Completed | Amgen | Jun 15, 2017 | 478 |
| NCT02335983Multiple Myeloma · United States | 1 | Completed | Amgen | Oct 28, 2019 | 107 |
| NCT01987232Small Cell Lung Carcinoma · United States, Canada, Russian Federation | 2 | Completed | Amgen | Aug 2016 | 32 |
| NCT01980589Multiple Myeloma · United States | 1 | Completed | Amgen | Mar 2016 | 22 |
| NCT01962792Multiple Myeloma · United States, Canada | 2 | Completed | AbbVie | Mar 2019 | 84 |
| NCT01949545Hematologic Neoplasms · United States, France, Netherlands and more | 1 | Completed | Amgen | Aug 2015 | 46 |
| NCT01949532Multiple Myeloma · United States, Australia, Canada | 1 | Completed | Amgen | Apr 2015 | 26 |
| NCT01818752Multiple Myeloma · United States, Argentina, Australia and more | 3 | Completed | Amgen | Jul 15, 2016 | 955 |
| NCT01789242Amyloidosis · United States | 1 | Completed | Criterium | Dec 2016 | 32 |
| NCT01792102Multiple Myeloma · United States | 2 | UNKNOWN | Oncotherapeutics | Dec 2018 | 38 |
| NCT01677858Multiple Myeloma · United States | 2 | Completed | Amgen | Jul 22, 2016 | 116 |
| NCT01660750Multiple Myeloma · United States | 1 | Completed | Criterium | Aug 2015 | 29 |
| NCT01568866Multiple Myeloma · United States, Australia, Austria and more | 3 | Completed | Amgen | Nov 10, 2014 | 929 |
| NCT01464034Multiple Myeloma · United States | 2 | Terminated | Criterium | Jul 2020 | 136 |
| NCT01302392Multiple Myeloma · Australia, Austria, Belgium and more | 3 | Completed | Amgen | Jul 2014 | 315 |
| NCT01080391Multiple Myeloma · United States, Austria, Belgium and more | 3 | Completed | Amgen | Jun 16, 2014 | 792 |
| NCT00884312Multiple Myeloma · United States, Canada | 2 | Completed | Amgen | May 17, 2017 | 101 |
| NCT00721734Multiple Myeloma · United States | 2 | Completed | Amgen | Nov 2012 | 50 |
| NCT00603447Multiple Myeloma · United States, Canada | 1 | Completed | Amgen | May 2013 | 84 |
| NCT00531284Ovarian Neoplasms · United States | 2 | Completed | Amgen | Oct 2014 | 184 |
| NCT00530816Multiple Myeloma · United States, Canada | 2 | Completed | Amgen | Jan 2013 | 164 |
| NCT00511238Multiple Myeloma · United States, Canada | 2 | Completed | Amgen | Nov 2010 | 312 |
| NCT00150462Waldenstrom Macroglobulinemia · United States | 1 | Completed | Amgen | Oct 2009 | 48 |
How it is read
Names in the registry
- “Carfilzomib”, 34 entries
- “carfilzomib”, 3 entries
- “Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®)”, 1 entry
- “Drug: Carfilzomib + Dexamethasone”, 1 entry
- “Drug: Carfilzomib + Lenalidomide + Dexamethasone”, 1 entry
Conditions, from the studies’ own filings
- Multiple Myeloma, 33 studies
- Amyloidosis, 1 study
- Small Cell Lung Carcinoma, 1 study
- Ovarian Neoplasms, 1 study
- Waldenstrom Macroglobulinemia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.